EFTA01100380.pdf

thoReference -tar LABORATORIES Final Report MI 1 FISCH, HARRY Specimen ID: 303053951 D HARRY FISCH M.D. IMAge: 62Y Sex: M Date Reported: 10130/2015 5:55 PM 0 C Date Collected: 10127/2015 4:44 PM T ACCT #: C1720 Date Received: 10/27/2015 11:42 PM Si O Source: URINE R F AUTOMATED UROVYSION TPA - FLUORESCENCE IN SITU HYBRIDIZATION (FISH) INTERPRETATION Negative for aneuploid cells. RESULTS No. of Cells Description 0 Aneuploid cells with extra signals, representing at least double aneuploidy of chromosomes 3. 7, and/or 17 0 Cells with loss of both gold (9p21) signals 102 Total cells scored • • • Two green. two red, two aqua. and two gold signals (x 1,000) INTERPRETIVE INFORMATION The UroVysion"" Bladder Cancer Kit (Vysis. Inc.) detects aneuploidy for chromosomes 3, 7. 17. and loss of the 9p21 locus via 4- color interphase FISH. It is FDA approved for use as an aid both in initial diagnosis of bladder cancer and for monitoring tumor recurrence on voided urine specimens in patients with transitional carcinoma of the bladder. Assessment of ploidy status was performed using an automated Fluorescence In Situ Hybridization (FISH) signal enumeration system (Metafer Slide Scanning System, MetaSystems Group Inc.. Watertown. MA). A maximum of 5000 cells are scanned. A positive/abnormal result requires 4 or more cells to show gain for 2 or more chromosomes (3. 7, and/or 17) in the same cell. or 12 or more cells to have zero 9p21 signals. A comparison of positive FISH results to cystoscopy/histology for detection of recurrent bladder cancer shows concordance in approximately 75% of cases, with the greatest correlation (up to 100%) in tumors of high grade and/or stage. The absence of detectable aneuploid cells does not exclude a bladder malignancy, nor does a negative result from a suboptimal specimen without the appropriate number of evaluable cells. Correlation with cytology and/or cystoscopic findings, as well as the patient's history and other laboratory tests is suggested. Pagel of 2 Y. Fan. M.D. BioReference Laboratories. Inc. James Weisberger. M.D. Created: 1030+20156:12 PM Hematopethologest 181 Edward H. Ross Drive Laboratory Director Electronically signed by P. S. Lee. M.D. Elmwood Park, NJ 07407 (800) 229-5227 Ig EFTA01100380 BioReference Final Report r LABORATORIES 1 FISCH, HARRY Specimen ID: 303053951 D HARRY Fl H M.D. A ff rge: 62Y Sex: M Date Reported: 10/30/2015 5:55 PM O C Date Collected: 10/27/2015 4:44 PM T ACCT S. C1720 I Date Received: 10/27/2015 11A2 PM St E Source: URINE R N T AUTOMATED UROVYSION TPA - FLUORESCENCE IN SITU HYBRIDIZATION (FISH) REFERENCES 1. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multicolor FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 116(1):79-86, 2001. 2. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol. 23(1):41-48, 2003. 3. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysionT" fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol. 22(1):16-19, 2004. 4. Vysis UroVysion TM Bladder Cancer Recurrence Kit Package Insert. Product Number 30-161070 and 36-161070, Vysis, Inc. 2004. The perlormance characteristics of this test were determined by BioReference Laboratories. It has been cleared by the U.S. Food and Drug Administration. These results may be used for clinical, investigational or for research purposes. and should be interpreted with other relevant clinicopathologic data. Page 2 of 2 Y. Fan. M.D. BioReference Laboratories. Inc. James Weisberger. M.D. Created: 10,30+20156:12 PM Hematopethologist 481 Edward H. Ross Drive Laboratory Director Elecbonicalty signed by P. S. Lee. M.D. Elmwood Park. NJ 07407 (800) 229-6227 Ig EFTA01100381